OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restruct

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while reta

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support,

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitabili

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining lo

The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license a

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preser

On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and oth

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b

Investors were also cheered by a substantial narrowing of the company's net loss. Ditto for the rais

OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lif

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Ph

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and

OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business perfor

OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estim

OPKO Health NASDAQ: OPK reported a narrower second-quarter loss as gains tied to its diagnostics res

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

OPKO Health (NASDAQ:OPK) raises FY2026 sales outlook from $530.000 million-$560.000 million to $560.

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.01) per share which beat the analyst conse

MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses a

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust

MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Hea

OPKO Health, Inc. (NASDAQ:OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (Eir

Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. P

Barrington Research analyst Michael Petusky downgrades OPKO Health (NASDAQ:OPK) from Outperform t

OPKO Health (NASDAQ:OPK) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.07) per share which met the analyst consen

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first partici

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform

2026 Financial Guidance: The table below reflects financial guidance for the first quarter and full

2026 Financial Guidance: The table below reflects financial guidance for the first quarter and full

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.04) per share which beat the analyst conse

This is the third program that successfully combines Entera's oral peptide N-Tab® platform with

Jefferies analyst Maury Raycroft downgrades OPKO Health (NASDAQ:OPK) from Buy to Hold and lowers

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered i

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion